| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | neurotrimin; NTM; NTRI; |
| Entrez GeneID | 50863; |
| WB Predicted band size | 42kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human NT. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于中和抗体(Neutralizing Antibodies，NT抗体)的3篇代表性文献摘要整理：
---
1. **文献名称**：*Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail*
**作者**：Hansen, J. 等
**摘要**：研究从COVID-19康复者中分离出针对SARS-CoV-2刺突蛋白的单克隆中和抗体，并通过人源化小鼠模型验证其强效中和能力，最终筛选出两种抗体组合(鸡尾酒疗法)，显著降低病毒逃逸风险并推进临床治疗应用。
2. **文献名称**：*SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness*
**作者**：Corbett, K.S. 等
**摘要**：分析mRNA疫苗(如Moderna mRNA-1273)诱导的中和抗体水平与保护效果的关系，发现高抗体效价与病毒中和活性正相关，为疫苗设计及评估提供了关键免疫学依据。
3. **文献名称**：*Passive immunotherapy of viral infections: supercharge antibodies*
**作者**：Walker, L.M. & Burton, D.R.
**摘要**：综述中和抗体在抗病毒治疗中的作用，涵盖HIV、流感等病毒，探讨通过结构生物学优化抗体结合位点及Fc段工程化改造以增强疗效的策略，推动被动免疫疗法的临床应用。
---
如需更特定领域的NT抗体研究(如神经科学)，建议补充具体背景信息。
**Background of NT Antibodies**
Neutralizing antibodies (NAbs), often referred to in the context of NT (neutralization test) antibodies, are specialized immunoglobulins that directly interfere with pathogenic infectivity by blocking interactions between pathogens and host cells. These antibodies target critical epitopes on viral surface proteins (e.g., SARS-CoV-2 spike protein) or bacterial toxins, preventing entry or activity. Their role in adaptive immunity is pivotal, as they neutralize pathogens before cellular invasion, offering sterilizing immunity.
The study of NT antibodies gained prominence with virology and vaccine development. Traditional neutralization tests, like plaque reduction neutralization tests (PRNT), measure antibody efficacy by quantifying pathogen neutralization in cell cultures. Such assays are gold standards for evaluating vaccine-induced immunity or natural infection responses. For instance, COVID-19 vaccine trials heavily relied on NT antibody titers to assess efficacy.
Advances in biotechnology have enabled high-throughput alternatives, such as pseudovirus-based neutralization assays or surrogate ELISA tests targeting receptor-binding domains. These methods address limitations of live-virus PRNTs, including biosafety concerns and labor intensity. However, correlations between surrogate assays and true neutralization remain under scrutiny.
NT antibodies also guide therapeutic development, including monoclonal antibody therapies (e.g., Regeneron’s COVID-19 antibody cocktail). Challenges persist, such as viral escape mutations reducing antibody efficacy, driving research into broadly neutralizing antibodies (bNAbs). Understanding NT antibody dynamics continues to shape vaccine design, immunotherapy, and pandemic preparedness strategies.
×
